Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dystrophin exon 51 pre-messenger RNA is a specific segment of the primary transcript of the DMD gene, which encodes the essential muscle protein dystrophin (UniProt P11532). In approximately 13% of patients with Duchenne muscular dystrophy (DMD), mutations disrupt the open reading frame, preventing the production of functional dystrophin and leading to severe, progressive muscle wasting (NIH, 2023). This pre-mRNA sequence serves as a therapeutic target for antisense oligonucleotides (ASOs) designed to induce "exon skipping." By binding to specific exonic splicing enhancer (ESE) sequences within exon 51, these drugs cause the cellular splicing machinery to bypass this exon during processing (FDA, 2016). This intervention restores the reading frame, allowing for the production of an internally truncated but partially functional dystrophin protein, effectively converting a severe DMD phenotype into a milder Becker-like muscular dystrophy phenotype (PubMed: 27638959).
Antisense oligonucleotide-mediated exon skipping to restore the mRNA reading frame.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dystrophin exon 51 pre-messenger RNA (DMD exon 51 pre-mRNA) (DMD exon 51 pre-mRNA).